Navigation Links
SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
Date:2/2/2009

ulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products and we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

    Contact:
    Investor Relations:
    Cameron Associates
    Kevin McGrath
    212.245.4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
2. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
3. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
4. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
5. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
6. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
7. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
8. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
9. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
10. China Biopharma, Inc. Issues Corporate Information Update
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... 2014 For many, fall turns daily life ... Ragweed is the most common cause of fall hay fever ... most common symptoms of ragweed allergy include a stuffed up ... allergy can also lead to wheezing, asthma attacks, and sinusitis. ... allergist about allergy immunotherapy - the only treatment shown to ...
(Date:8/31/2014)... order to celebrate the coming of autumn, Guangdong FODAY ... a big promotion. Now, all the global clients can access ... cars are made with great materials. FODAY Automobile strives to ... matter of fact, it is providing big discounts on many ... of cheap cars can visit its website for more details. ...
(Date:8/31/2014)... 2014 LabDoor.com tests the purity and ... According to their website, “We buy products in the ... stores and online sites. No manufacturer-supplied samples are permitted ... Healthy with LabDoor,” a recent study was performed on ... in the United States for Vitamin D3 content, heavy ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 In the ... of states have proposed legislation to require mandatory labeling ... can make informed purchasing decisions that affect their own ... industry leader advocating for stringent measures to eliminate GMOs ... its “Information, Communication, Engagement” (I.C.E.) initiative with the objective ...
(Date:8/31/2014)... 2014 Twin to twin transfusion syndrome (TTTS) ... Colp before they were born, but an innovative fetal surgery at ... the chance at life. , Now, their parents David and Theresa ... surgery option available in St. Louis at the St. Louis Fetal ... Market Pub House (6655 Delmar Blvd, St Louis, MO 63130) on ...
Breaking Medicine News(10 mins):Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 3
... fasciitis, researchers say , , MONDAY, Dec. 1 (HealthDay ... fast, effective, non-invasive treatment for the painful foot ... combination of "dry-needling" and steroid injections guided by ... 95 percent success rate in tackling a condition ...
... NASHVILLE, Tenn., Dec. 1 Medication therapy management,(MTM) provider ... , New members ... Burcham; and Kevin Hutchinson. The three join an ... hone its MTM services, which work,to guard against medication ...
... take a close look at,the Part D drug coverage ... year. Medicare HMO and PPO plans in many ... deductibles with partial coverage,throughout the "gap" or "donut hole" ... $4,350 in out-of-pocket costs). HealthMetrix,Research Inc. screened over ...
... visit a dentist,in the mid-Michigan area, don,t be surprised if ... , Delta Dental of ... Care Association are spearheading a pilot,project designed to have dentists ... in patients. , "Dentists ...
... according to a large study performed at Leiden University ... study consisted of 1,331 patients who had suspected coronary ... artery segments were analyzed during the study. "We found ... stenosis in our patients; specificity was 91%," said Lucia ...
... shows for the first time how microscopic crystals form sound ... ends of cilia tiny cellular hairs in the ear ... important role in detecting sound, maintaining balance and regulating movement. ... for the most common form of vertigo. Known as benign ...
Cached Medicine News:Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:PharmMD Expands Advisory Board 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2009 Out-of-Pocket Drug Costs 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 3Health News:Can you hear me now? How the inner ear's sensors are made 2
(Date:8/29/2014)... , Aug. 29, 2014 Does your doctor ... nearly 800 doctors have recommended marijuana to the over 112,000 ... 20. But the majority of the other roughly 20,300+ active ... know very little about it – even though a poll ... adults say they have tried it. ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... CITY, Calif. , Aug. 29, 2014  Abaxis, ... company manufacturing point-of-care blood instrumentation and consumables to the ... Clint Severson , Chairman and Chief Executive Officer, will ... Best Ideas Conference 2014 on Tuesday, September 9, 2014 ... at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... as We Age, Becomes Squarer, Makes You Look Older, ... Your face,may be giving away your age, and it ... eyelids. A study in January,s Plastic and,Reconstructive Surgery(R) (PRS), ... Surgeons (ASPS), found that as we age, the,lower jaw ...
... Colo. and MONTREAL, Jan. 9 Pharmion,Corporation ... (TSX: MYG) today announced,the enrollment of the ... trial (Trial,CL002) evaluating MGCD0103, the Companies, isotype-selective ... with,Vidaza(R) (azacitidine for injection), Pharmion,s DNA demethylating ...
Cached Medicine Technology:Looking Older? How Square is Your Jaw Line? 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 3Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 4Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 5Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 6Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 7
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
Medicine Products: